Drug intelligence / Profile preview

oxantel

Development stage
Phase 4
Lead developer
Drugs for Neglected Diseases initiative
Modality
Small Molecules
Administration
Oral
01

Overview

Oxantel is a narrow-spectrum anthelmintic drug primarily used to treat intestinal worm infections, especially those caused by whipworm (Trichuris trichiura), as well as other nematodes such as Ascaris and Enterobius species. It is structurally related to pyrantel and acts mainly by depolarizing neuromuscular blocking action in susceptible worms. Oxantel functions as an agonist at specific nicotinic acetylcholine receptor subtypes (notably the N-type or O-AChR subtype) in nematodes, leading to spastic paralysis of the parasite[1][3][4]. Additionally, it has been shown to inhibit fumarate reductase in some pathogenic bacteria and disrupt biofilm formation by Porphyromonas gingivalis[5][7]. The drug is administered orally and is often combined with pyrantel for broader antihelminthic coverage. Oxantel has been widely used in both human and veterinary medicine.

Brand names
Telopar
Other names
oxantel pamoate
02

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on oxantel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxantel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call